Monika Mochol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Monika Mochol has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Erik Taubøll
Institute of Clinical Medicine, University of Oslo, PO box 1072 Blindern, 0316 Oslo, Norway
2 shared publicationsSigrid Svalheim
ERGO - Epilepsy Research Group of Oslo, Department of Neurology, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway
2 shared publicationsBjørn Tennøe
Department of Radiology and Nuclear Medicine, Oslo University Hospital, PO box 4950 Nydalen, 0424 Oslo, Norway
1 shared publicationEmilia Kerty
1 shared publication- Erik Taubøll
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Division of Clinical Neuroscience, Department of Neurology, Oslo University Hospital, Oslo, Norway
1 shared publication - Geir Ringstad
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
1 shared publication
Latest Publications
- Open Access
- 7 February 2023
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 2023, 1-5
Serum Markers of Neuronal Damage and Astrocyte Activity in Patients with Chronic Epilepsy: Elevated Levels of Glial Fibrillary Acidic Protein
Objectives. Blood-brain barrier (BBB) dysfunction is one of the key pathogenic mechanisms in the development of epilepsy. There is therefore an increasing need to identify BBB biomarkers as these will have prognostic and therapeutic implications. The purpose of this study was to assess the levels of the BBB permeability markers, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), S100B, and furin in patients with stable epilepsy compared with the levels in healthy controls. Materials and Methods. This cross-sectional study included 119 epilepsy patients and 80 healthy controls. Circulating levels of GFAP, NSE, S100B, and furin were measured and questionnaires regarding epilepsy, use of drugs, and comorbidities were completed by all participants. Results. GFAP levels were higher in epilepsy patients after adjustment for potential confounders (sex, age, and BMI) in linear regression ( p = 0.042 ). No significant differences were found in levels of S100B, NSE, or furin. None of the markers were significantly associated with epilepsy duration, seizure type or severity, or seizures in the preceding six months. The majority of the patients (79.7%) did not report seizures within the last 6 months. Conclusion. Our main finding is elevated serum levels of GFAP in epilepsy patients. The results may suggest the presence of astrocyte activation in our patient population with stable epilepsy. Future prospective studies focusing on the longitudinal relationship between epilepsy debut, seizures, and time of blood sampling for BBB markers, also within CSF, could provide valuable knowledge including regarding novel treatment options. The study registration number is 2011/1096, 2018/1437.
- 7 February 2023
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 2023, 1-5
Open AccessSerum Markers of Neuronal Damage and Astrocyte Activity in Patients with Chronic Epilepsy: Elevated Levels of Glial Fibrillary Acidic Protein
Objectives. Blood-brain barrier (BBB) dysfunction is one of the key pathogenic mechanisms in the development of epilepsy. There is therefore an increasing need to identify BBB biomarkers as these will have prognostic and therapeutic implications. The purpose of this study was to assess the levels of the BBB permeability markers, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), S100B, and furin in patients with stable epilepsy compared with the levels in healthy controls. Materials and Methods. This cross-sectional study included 119 epilepsy patients and 80 healthy controls. Circulating levels of GFAP, NSE, S100B, and furin were measured and questionnaires regarding epilepsy, use of drugs, and comorbidities were completed by all participants. Results. GFAP levels were higher in epilepsy patients after adjustment for potential confounders (sex, age, and BMI) in linear regression ( p = 0.042 ). No significant differences were found in levels of S100B, NSE, or furin. None of the markers were significantly associated with epilepsy duration, seizure type or severity, or seizures in the preceding six months. The majority of the patients (79.7%) did not report seizures within the last 6 months. Conclusion. Our main finding is elevated serum levels of GFAP in epilepsy patients. The results may suggest the presence of astrocyte activation in our patient population with stable epilepsy. Future prospective studies focusing on the longitudinal relationship between epilepsy debut, seizures, and time of blood sampling for BBB markers, also within CSF, could provide valuable knowledge including regarding novel treatment options. The study registration number is 2011/1096, 2018/1437.
- Open Access
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 16, 100462
Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen’s encephalitis
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 16, 100462
Open AccessSeizure control after late introduction of anakinra in a patient with adult onset Rasmussen’s encephalitis
- 1 August 2020
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 80, 221-225
Interleukin 18 (IL-18) and its binding protein (IL-18BP) are increased in patients with epilepsy suggesting low-grade systemic inflammation
- 1 August 2020
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 80, 221-225
Interleukin 18 (IL-18) and its binding protein (IL-18BP) are increased in patients with epilepsy suggesting low-grade systemic inflammation
- Open Access
- 1 July 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (12/13) , 1245-8
Kvinne med residiverende uveitter og nevrologiske utfall
En kvinne i 40-årene ble innlagt ved universitetssykehus med to ukers sykehistorie med økende hodepine, gangvansker og nedsatt allmenntilstand. Hun hadde mange års sykehistorie med uveitter og nevrologiske symptomer bak seg, men på tross av omfattende utredning var diagnosen fortsatt usikker.
- 1 July 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (12/13) , 1245-8
Open AccessKvinne med residiverende uveitter og nevrologiske utfall
En kvinne i 40-årene ble innlagt ved universitetssykehus med to ukers sykehistorie med økende hodepine, gangvansker og nedsatt allmenntilstand. Hun hadde mange års sykehistorie med uveitter og nevrologiske symptomer bak seg, men på tross av omfattende utredning var diagnosen fortsatt usikker.